These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28616823)

  • 1. Population Pharmacokinetics of Combined Intravenous and Local Intrathecal Administration of Meropenem in Aneurysm Patients with Suspected Intracranial Infections After Craniotomy.
    Li X; Sun S; Wang Q; Zhao Z
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):45-53. PubMed ID: 28616823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and cerebrospinal fluid population pharmacokinetic modeling and simulation of meropenem after intravenous and intrathecal administration in postoperative neurosurgical patients.
    Li X; Wang X; Wu Y; Sun S; Chen K; Lu Y; Wang Q; Zhao Z
    Diagn Microbiol Infect Dis; 2019 Apr; 93(4):386-392. PubMed ID: 30638947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration.
    Li X; Sun S; Ling X; Chen K; Wang Q; Zhao Z
    Eur J Clin Pharmacol; 2017 Dec; 73(12):1599-1607. PubMed ID: 28849406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Influencing Norvancomycin Concentration in Plasma and Cerebrospinal Fluid in Patients After Craniotomy and Dosing Guideline: A Population Approach.
    Li X; Wu Y; Sun S; Wang Q; Zhao Z
    Clin Ther; 2018 Jan; 40(1):74-82.e1. PubMed ID: 29229228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery.
    Lu C; Zhang Y; Chen M; Zhong P; Chen Y; Yu J; Wu X; Wu J; Zhang J
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6619-6625. PubMed ID: 27572392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
    Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
    Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study.
    Blassmann U; Roehr AC; Frey OR; Vetter-Kerkhoff C; Thon N; Hope W; Briegel J; Huge V
    Crit Care; 2016 Oct; 20(1):343. PubMed ID: 27776537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy.
    Chen K; Wu Y; Wang Q; Wang J; Li X; Zhao Z; Zhou J
    J Crit Care; 2015 Feb; 30(1):218.e1-5. PubMed ID: 25449880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined intravenous and intrathecal vancomycin in treatment of patients with intracranial infections after craniotomy].
    Bao Y; Qiu B; Zeng H; Mo Y; Zhang N; Qi S
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2016 Feb; 28(2):169-72. PubMed ID: 26911951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
    Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
    Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
    Lodise TP; Nau R; Kinzig M; Drusano GL; Jones RN; Sörgel F
    J Antimicrob Chemother; 2007 Nov; 60(5):1038-44. PubMed ID: 17785282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
    Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
    J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery.
    Zhang Y; Zhang J; Chen Y; Yu J; Cao G; Wu X; Chen M; Wu J; Zhao X
    World Neurosurg; 2017 Feb; 98():525-531. PubMed ID: 27867128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short versus long infusion of meropenem in very-low-birth-weight neonates.
    Padari H; Metsvaht T; Kõrgvee LT; Germovsek E; Ilmoja ML; Kipper K; Herodes K; Standing JF; Oselin K; Lutsar I
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4760-4. PubMed ID: 22733063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
    Dandekar PK; Maglio D; Sutherland CA; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2003 Aug; 23(8):988-91. PubMed ID: 12921245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
    Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
    Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.